NCT00002240已完成2 期
Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen
Bristol-Myers Squibb31 个研究点 分布在 2 个国家开始时间: 1999年3月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 31
研究概览
简要总结
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.
详细描述
Patients are randomized to receive one of two drug regimens: BMS-232632, ddI, and d4T or NFV, ddI, and d4T. Three different doses of BMS-232632 are used in this study. Randomization is stratified for HIV RNA level (less than 30,000 copies/ml versus 30,000 or greater copies/ml). Patients remain on their drug regimen for 48 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (31)
Loading locations...
相似试验
已完成
3 期
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-LamivudineHIV InfectionsNCT00013897Bristol-Myers Squibb
已完成
2 期
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)Hepatitis C, ChronicNCT00774397Boehringer Ingelheim719
已完成
1 期
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1Chronic Genotype 1 Hepatitis C Virus InfectionNCT01247194Presidio Pharmaceuticals, Inc.24
终止
4 期
A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic SyndromeHIV InfectionsNCT00312754Bristol-Myers Squibb70
已完成
2 期
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland ChinaHepatitis B, ChronicNCT04507269Brii Biosciences Limited21